Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs

Shuang Wang; Zhenye Xu; Lifang Wang

doi:10.18632/oncotarget.19129

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs

Shuang Wang, Zhenye Xu _ and Lifang Wang

PDF | HTML | Supplementary Files | How to cite

Oncotarget. 2017; 8:62154-62166. https://doi.org/10.18632/oncotarget.19129

Metrics: PDF 1371 views | HTML 2285 views | ?

Abstract

Shuang Wang1,2, Zhenye Xu1 and Lifang Wang1

1Department of Oncology II, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200032, China

2Department of Oncology, Seventh People’s Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 200137, China

Correspondence to:

Zhenye Xu, email: [email protected]

Lifang Wang, email: [email protected]

Keywords: cyclophosphamide, lung cancer, myelosuppression, Shuanghuang Shengbai granule, white blood cells

Received: August 15, 2016 Accepted: June 02, 2017 Published: July 10, 2017

ABSTRACT

Background: Shuanghuang Shengbai granule is effective in curing cyclophosphamide-induced myelosuppression without promoting lung cancer development. This study aims to investigate its mechanism and therapeutic targets.

Methods: Nude mice with lung cancer were treated with physiological saline (control), cyclophosphamide, or cyclophosphamide + Shuanghuang Shengbai. MicroRNA microarray was used to investigate the differentially expressed microRNAs in lung cancer stem cells or bone marrow hematopoietic stem cells between the three groups. MicroRNA expressions were confirmed using quantitative real time-polymerase chain reaction.

Results: Cyclophosphamide suppressed tumor growth and decreased the ratio of SP⁺ lung cancer stem cells (P<0.05). Shuanghuang Shengbai further decreased the ratios of SP⁺ and CD24⁺IGF1R⁺ lung cancer stem cells (P<0.05). Shuanghuang Shengbai completely reversed the cyclophosphamide-induced decreases in white blood cells, proliferation index of bone marrow cells, and the ratio of CD34⁺SCA1⁺ bone marrow hematopoietic stem cells (P<0.05). We found 45 and 343 altered microRNAs for SP⁺ lung cancer stem cells and CD34⁺SCA1⁺ bone marrow hematopoietic stem cells, respectively. Moreover, miR-32*, miR-466i-5p, and mmu-miR-669c in SP⁺ lung cancer stem cells were confirmed, as well as mmu-miR-106b*, mmu-miR-144, mmu-miR-669k*, mmu-miR-142-3p, mmu-miR-210, and mmu-miR-223 in CD34⁺SCA1⁺ bone marrow hematopoietic stem cells.

Conclusion: Shuanghuang Shengbai might promote the proliferation of CD34⁺SCA1⁺ bone marrow hematopoietic stem cells via up-regulating mmu-miR-106b*, mmu-miR-144, and mmu-miR-669k*, as well as down-regulating mmu-miR-142-3p, mmu-miR-210, and mmu-miR-223. Shuanghuang Shengbai might further inhibit the proliferation of SP⁺ lung cancer stem cells via enhancing the expressions of miR-32*, miR-466i-5p, and mmu-miR-669c. These might be the mechanism and therapeutic targets of Shuanghuang Shengbai granule.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 19129

Publication Alerts

Research Papers:

Shuanghuang Shengbai granule cures myelosuppression and suppresses lung cancer progression: mechanism and therapeutic targets from the aspect of microRNAs

Abstract